Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Valuation & Earnings
This table compares Fulcrum Therapeutics and Eton Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fulcrum Therapeutics | $81.63 million | 6.42 | -$97.33 million | ($1.60) | -5.27 |
| Eton Pharmaceuticals | $31.64 million | 3.90 | -$940,000.00 | $0.04 | 119.50 |
Eton Pharmaceuticals has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fulcrum Therapeutics | 0 | 1 | 6 | 0 | 2.86 |
| Eton Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Fulcrum Therapeutics presently has a consensus target price of $15.43, indicating a potential upside of 83.02%. Eton Pharmaceuticals has a consensus target price of $8.50, indicating a potential upside of 77.82%. Given Fulcrum Therapeutics’ higher probable upside, research analysts clearly believe Fulcrum Therapeutics is more favorable than Eton Pharmaceuticals.
Volatility & Risk
Fulcrum Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
Profitability
This table compares Fulcrum Therapeutics and Eton Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fulcrum Therapeutics | -3,470.05% | -8.28% | -7.61% |
| Eton Pharmaceuticals | -21.31% | -43.62% | -21.25% |
Insider & Institutional Ownership
89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Fulcrum Therapeutics beats Eton Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
